AbCellera Biologics (ABCL) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
8 analysts covering AbCellera Biologics (ABCL) carry an average price target of $10.50 as of August 2026, +83.9% against the $5.71 price at the time of the pull. The published targets run from $7.00 to $13.00, a spread of 57% of the average, so the disagreement is moderate. The rating split is 9 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.
ABCL analyst price targets
ABCL analyst data as of August 2026, sourced from Yahoo Finance and may be delayed. A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.
The average target of $10.50 sits well above the $5.71 price, +83.9%. The median is $11.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.
What the ABCL target range actually tells you
The published targets span $7.00 to $13.00. That gap is 57% of the average target, which counts as moderate disagreement. That is a fairly typical spread: enough agreement that the average means something, enough disagreement that it should not be treated as precise.
The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the ABCL is it a buy page.
Recent analyst actions on ABCL
| Firm | Action | Target | Prior | Date |
|---|---|---|---|---|
| Benchmark | Initiated (Buy) | $11.00 | - | July 7, 2026 |
| Cantor Fitzgerald | Initiated (Overweight) | $7.00 | - | May 5, 2026 |
| Jones Trading | Initiated (Buy) | $11.00 | - | April 10, 2026 |
The most recent published rating actions on ABCL within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.
In the last six months there have been 0 raises and 0 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.
How analysts rate ABCL
Of the analysts with a published rating, 9 say buy, 0 say hold, and 0 say sell, so 100% carry a buy. That buy share has risen over the last three months, so sentiment is drifting more positive.
Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.
Why a ABCL price target is not a prediction
- It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
- The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
- Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
- Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.
What could move ABCL from here
In short: the drivers cited most often are Own-pipeline catalysts in 2026, Deep cash runway, Platform and royalty optionality. The risk cited most often against it is abCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ABCL is it a buy page. This page deliberately stops at the numbers.
Investing in AbCellera Biologics with AI
Connect the broker you already use and ask Walnut's AI how ABCL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for AbCellera Biologics (ABCL)?
+
The average analyst price target for ABCL is $10.50 as of August 2026, across 8 analysts. That is +83.9% against the $5.71 price at the time of the data pull, so the consensus sits well above where the stock trades. The median target, which is less distorted by one extreme view, is $11.00. Targets move constantly; verify the current figure before relying on it.
How high could ABCL go?
+
The highest published target is $13.00, which is +127.7% against the $5.71 price. That is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $7.00. The gap between them is the honest answer to this question: analysts who all follow AbCellera Biologics closely disagree by 57% of the average target, so treat any single number as one scenario.
How many analysts cover ABCL?
+
8 analysts publish estimates on ABCL as of August 2026. Of those with a published rating, 9 say buy, 0 hold, and 0 sell, so 100% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.
Are analyst price targets for ABCL accurate?
+
Treat them as informed opinion, not measurement. Two things are worth knowing. Sell-side ratings skew positive across the market, and ABCL is no exception at 100% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.
Has the ABCL price target been raised or cut recently?
+
In the last six months there have been 0 raises and 0 cuts among the published actions on ABCL. The most recent was Benchmark, which initiated its target to $11.00 on July 7, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.
Is analyst sentiment on ABCL improving?
+
Over the last three months the share of analysts rating ABCL a buy has been rising. That is a shift in opinion, not in the business, and it often lags the news that caused it. It is worth watching alongside the target revisions rather than on its own.
Will ABCL go up in 2026?
+
Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is genuinely useful and completely different from a prediction. The risk most often cited against AbCellera Biologics: AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Walnut is not an investment adviser.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a August 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.